2023-03-14| Special

Biotech Start-ups May Face a Foreboding Prospect Following Silicon Valley Bank (SVB)’s Unsuspected Collapse

by Richard Chau
Share To
Silicon Valley Bank (SVB), the 16th largest bank in the United States with total assets of $209 billion and deposits of $175.4 billion (as of the end of 2022), has recently suffered a major financial meltdown, as its shares plummeted precipitously and about $42 billion in deposits were withdrawn in a run. Despite selling its assets and stocks immediately to raise the necessary funds, SVB failed to save itself and went bankrupt last week. As a result, the bank was taken over by the Federal Deposit Insurance Corporation (FDIC).

The collapse of SVB is the largest failure of a financial institution in the United States since the 2008 financial crisis (and the second largest ever). According to SVB, nearly half of all venture-backed technology and biotech start-ups in the U.S. have opened accounts with the bank, amounting to approximately $342 billion in client funds and involving approximately $74 billion in loans. Therefore, the incident is bound to create a substantial impact on the global biotech industry, especially those venture-backed companies.

It's free! Log in now to read

Company Presentations at BIO 2024 Inspire Partnering
GV Regains Compliance with Nasdaq Minimum Bid Price Requirement
ARPA-H Fast-Tracks Biotech Startups: Funding Insights from BIO 2024 Panel
Gene Therapy Innovations and Financial Challenges for the Future of Medicine
BIO Releases DEI Survey in Partnership with Korn Ferry
Advancing Healthcare Accessibility and Sustainable Development
New CRISPR Method Enables Gene Edits in Cockroaches and All Insects
Scroll to Top